Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc.XERS · Entity 4670 | See Remarks | October 01, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Xeris Biopharma Holdings, Inc.
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,599,208 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Sale · Disposed 15,000 · Balance 1,599,208 F1: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2025. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.180 to $9.665, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 25,000 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 25,000 F3: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2025.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.180 to $9.665, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 3, 2026 00:54 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | SaleCommon Stock | 15,000 | $9.41 | $141,120.00 |
DisclosureSEC source: 0001867096-26-000085 · wk-form4_1790974469.xml · nonDerivative · entry 1 McCulloch Kevin · CIK 0002031695 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,599,208 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.180 to $9.665, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 28, 2026 Filed Sep 29, 2026 20:59 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | SaleCommon Stock | 25,000 | $10.00 | $250,000.00 |
DisclosureSEC source: 0001867096-26-000078 · wk-form4_1790715570.xml · nonDerivative · entry 1 McCulloch Kevin · CIK 0002031695 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,614,208 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2025. Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 22:21 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | SaleCommon Stock | 15,000 | $8.49 | $127,308.00 |
DisclosureSEC source: 0002031695-26-000011 · wk-form4_1788301275.xml · nonDerivative · entry 1 McCulloch Kevin · CIK 0002031695 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,639,208 F1 · kind: The transaction was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on September 4, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.390 to $8.600, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 21:30 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | SaleCommon Stock | 15,000 | $8.02 | $120,240.00 |
DisclosureSEC source: 0001867096-26-000059 · wk-form4_1785879024.xml · nonDerivative · entry 1 McCulloch Kevin · CIK 0002031695 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,676,126 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.000 to $8.150, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 01, 2026 Filed Aug 21, 2026 20:15 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 21,918 | $8.08 | $177,097.44 |
DisclosureSEC source: 0001867096-26-000069 · wk-form4_1787343331.xml · nonDerivative · entry 1 McCulloch Kevin · CIK 0002031695 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,654,208 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of August 1, 2026. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 20:40 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | SaleCommon Stock | 90,000 | $8.03 | $722,511.00 |
DisclosureSEC source: 0002031695-26-000008 · wk-form4_1783024852.xml · nonDerivative · entry 1 McCulloch Kevin · CIK 0002031695 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,691,126 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person as of September 4, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.000 to $8.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 3,401 shares acquired on June 30, 2026 under the issuer's 2018 Employee Stock Purchase Plan, as amended. Read SEC document |
| March 12, 2026 Filed Mar 16, 2026 22:11 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4 | $3.94 Strike: $3.94 | $15.76 |
DisclosureSEC source: 0002031695-26-000006 · wk-form4_1773699093.xml · derivative · entry 5 McCulloch Kevin · CIK 0002031695 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,996 Underlying: Common Stock · 4 shares Expires 2030-08-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The reporting person received the stock options on August 26, 2020 pursuant to an award under the 2018 Plan. 50% of the options vested on the first anniversary of the vesting commencement date, 25% of the options vested on the 18-month anniversary of the vesting commencement date, and the remaining 25% of options vested on the two-year anniversary of the vesting commencement date, in each case subject to continued employment through such vesting date. Read SEC document |
| March 12, 2026 Filed Mar 16, 2026 22:11 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Exercise / conversionStock Option (Right to Buy) · Derivative | 48,894 | $4.09 Strike: $4.09 | $199,976.46 |
DisclosureSEC source: 0002031695-26-000006 · wk-form4_1773699093.xml · derivative · entry 4 McCulloch Kevin · CIK 0002031695 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,773 Underlying: Common Stock · 48,894 shares Expires 2027-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The reporting person received the stock options on December 10, 2020 pursuant to an award under the Company's 2018 Stock Option/Stock Issuance Plan (the "2018 Plan"). 50% of the options vested on the first anniversary of the vesting commencement date, and the remaining 50% of options vested on the second anniversary of the vesting commencement date, in each case subject to continued employment through such vesting date. Read SEC document |
| March 12, 2026 Filed Mar 16, 2026 22:11 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Exercise / conversionCommon Stock | 4 | $3.94 | $15.76 |
DisclosureSEC source: 0002031695-26-000006 · wk-form4_1773699093.xml · nonDerivative · entry 2 McCulloch Kevin · CIK 0002031695 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,777,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2026 Filed Mar 16, 2026 22:11 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Exercise / conversionCommon Stock | 48,894 | $4.09 | $199,976.46 |
DisclosureSEC source: 0002031695-26-000006 · wk-form4_1773699093.xml · nonDerivative · entry 1 McCulloch Kevin · CIK 0002031695 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,777,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2026 Filed Feb 2, 2026 23:12 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 27,319 | $7.36 | $201,067.84 |
DisclosureSEC source: 0002031695-26-000004 · wk-form4_1770073970.xml · nonDerivative · entry 4 McCulloch Kevin · CIK 0002031695 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,727,827 F2 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2026. Read SEC document |
| January 31, 2026 Filed Feb 2, 2026 23:12 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 30,289 | $7.36 | $222,927.04 |
DisclosureSEC source: 0002031695-26-000004 · wk-form4_1770073970.xml · nonDerivative · entry 3 McCulloch Kevin · CIK 0002031695 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,755,146 F2 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2026. Read SEC document |
| January 31, 2026 Filed Feb 2, 2026 23:12 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 68,454 | $7.36 | $503,821.44 |
DisclosureSEC source: 0002031695-26-000004 · wk-form4_1770073970.xml · nonDerivative · entry 2 McCulloch Kevin · CIK 0002031695 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,785,435 F2 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2026. Read SEC document |
| January 30, 2026 Filed Feb 2, 2026 23:12 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantStock Option (Right to Buy) · Derivative | 225,225 | $0.00 Strike: $7.36 | $0.00 |
DisclosureSEC source: 0002031695-26-000004 · wk-form4_1770073970.xml · derivative · entry 6 McCulloch Kevin · CIK 0002031695 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,225 Underlying: Common Stock · 225,225 shares Expires 2036-01-30 F4 · derivative.exercise_date: These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in equal annual installments over three years, subject to continued service through such vesting date. Read SEC document |
| January 30, 2026 Filed Feb 2, 2026 23:12 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantCommon Stock | 168,463 | $0.00 | $0.00 |
DisclosureSEC source: 0002031695-26-000004 · wk-form4_1770073970.xml · nonDerivative · entry 1 McCulloch Kevin · CIK 0002031695 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,853,889 F1 · shares: These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued employment through such vesting date. Read SEC document |
| January 08, 2026 Filed Jan 9, 2026 22:34 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | SaleCommon Stock | 15,000 | $8.00 | $120,000.00 |
DisclosureSEC source: 0002031695-26-000002 · wk-form4_1767998094.xml · nonDerivative · entry 1 McCulloch Kevin · CIK 0002031695 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,685,426 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 21:21 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 733 | $8.31 | $6,091.23 |
DisclosureSEC source: 0002031695-25-000006 · wk-form4_1759526468.xml · nonDerivative · entry 1 McCulloch Kevin · CIK 0002031695 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,700,426 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of October 2, 2025. Read SEC document |
| September 11, 2025 Filed Sep 15, 2025 21:33 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | OtherCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0002031695-25-000004 · wk-form4_1757971992.xml · nonDerivative · entry 1 McCulloch Kevin · CIK 0002031695 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By Charles R. McCulloch Trust dated 1990 Disclosed balance after: 0 F1 · kind: The reporting person is trustee of the Charles R. McCulloch Trust, of which he is a beneficiary. On September 11, 2025, the reporting person caused the trust to distribute 2,000 shares of the Issuer's common stock to a beneficiary of the trust. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. No sale of shares occurred in the transfer. Read SEC document |
| August 01, 2025 Filed Aug 4, 2025 20:24 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 14,651 | $5.38 | $78,822.38 |
DisclosureSEC source: 0001867096-25-000123 · wk-form4_1754339070.xml · nonDerivative · entry 1 McCulloch Kevin · CIK 0002031695 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,701,159 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of August 1, 2025. F2 · balance_after: These shares include 7,225 shares that were purchased on June 30, 2025 due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan. Read SEC document |
| June 13, 2025 Filed Jun 16, 2025 20:26 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | PurchaseCommon Stock | 25,000 | $4.38 | $109,475.00 |
DisclosureSEC source: 0001867096-25-000118 · wk-form4_1750105556.xml · nonDerivative · entry 1 McCulloch Kevin · CIK 0002031695 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,708,585 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.3750 to $4.380, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| April 02, 2025 Filed Apr 3, 2025 20:20 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 733 | $5.15 | $3,774.95 |
DisclosureSEC source: 0001867096-25-000060 · wk-form4_1743711598.xml · nonDerivative · entry 1 McCulloch Kevin · CIK 0002031695 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,683,585 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of April 2, 2025. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 00:40 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantStock Appreciation Right · Derivative | 500,000 | $0.00 Strike: $3.56 | $0.00 |
DisclosureSEC source: 0001867096-25-000027 · wk-form4_1738629632.xml · derivative · entry 6 McCulloch Kevin · CIK 0002031695 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2027-03-02 F4 · derivative.exercise_date: This stock appreciation right granted under the Company's 2018 Stock Option and Incentive Plan will vest in full on the second anniversary of the January 31, 2025 grant date, subject to continued service with the company through the vesting date. F5 · derivative.underlying: Upon exercise, the stock appreciation right will be settled in cash. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 00:40 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantCommon Stock | 185,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001867096-25-000027 · wk-form4_1738629632.xml · nonDerivative · entry 3 McCulloch Kevin · CIK 0002031695 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,684,318 F2 · shares: These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 00:40 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 48,834 | $3.56 | $173,849.04 |
DisclosureSEC source: 0001867096-25-000027 · wk-form4_1738629632.xml · nonDerivative · entry 2 McCulloch Kevin · CIK 0002031695 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,499,318 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2025. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 00:40 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 29,300 | $3.56 | $104,308.00 |
DisclosureSEC source: 0001867096-25-000027 · wk-form4_1738629632.xml · nonDerivative · entry 1 McCulloch Kevin · CIK 0002031695 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,548,152 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2025. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:42 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Tax withholdingCommon Stock | 24,501 | $3.61 | $88,448.61 |
DisclosureSEC source: 0001867096-25-000014 · wk-form4_1736286172.xml · nonDerivative · entry 1 McCulloch Kevin · CIK 0002031695 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,577,452 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of Restricted Stock Units vested as of January 3, 2025. Read SEC document |
| August 01, 2024 Filed Aug 2, 2024 21:22 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantStock Appreciation Right · Derivative | 200,000 | $0.00 Strike: $2.43 | $0.00 |
DisclosureSEC source: 0001867096-24-000144 · wk-form4_1722633751.xml · derivative · entry 2 McCulloch Kevin · CIK 0002031695 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2026-09-01 F1 · derivative.exercise_date: The award will vest in full on the two-year anniversary of the grant date. F2 · derivative.underlying_shares: Upon exercise, the Stock Appreciation Right will be settled in cash. Read SEC document |
| August 01, 2024 Filed Aug 2, 2024 21:22 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001867096-24-000144 · wk-form4_1722633751.xml · nonDerivative · entry 1 McCulloch Kevin · CIK 0002031695 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,601,953 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.